<PAGE>

                                                                    EXHIBIT 10.1

                                                                  EXECUTION COPY

                         GENERIC DISTRIBUTION AGREEMENT

     This Generic Distribution Agreement (this "Agreement") is entered into as
of February 12, 2006 (the "Effective Date") by and between King Pharmaceuticals,
Inc., a Tennessee corporation with a principal place of business at 501 Fifth
Street, Bristol, TN 37620, USA ("King"), and Cobalt Pharmaceuticals, Inc., a
Canadian company with a principal place of business at 6500 Kitimat Road,
Mississauga, Ontario LN5 2Bb, Canada ("Cobalt"). King and Cobalt are
collectively referred to herein as the "Parties" and individually as a "Party."

                                    RECITALS

     WHEREAS, King sells the Branded Product (as hereinafter defined) branded
under the name Altace(R) in a capsule form in the Territory (as hereinafter
defined);

     WHEREAS, Cobalt desires to distribute a Generic Product (as hereinafter
defined) in capsule form in the Territory; and

     WHEREAS, Cobalt seeks to have King manufacture and supply, and King seeks
to manufacture and supply to Cobalt, a Generic Product for distribution in the
Territory;

     NOW, THEREFORE, in accordance with the foregoing recitals, and in
consideration of the mutual covenants contained herein, the Parties agree as
follows:

                                    AGREEMENT

1.   DEFINITIONS

     1.1 "Act" means the United States Federal Food, Drug and Cosmetic Act, as
amended.

     1.2 "Action" has the meaning set forth in Section 3.12(a).

     1.3 "Affiliate" means any corporation, firm, partnership, or other entity
that directly or indirectly controls or is controlled by or is under common
control with a party. For purposes of this definition, "control" means
ownership, directly or through one or more Affiliates of (a) fifty percent (50%)
or more of the shares or voting rights in case of corporation or limited
company, (b) fifty percent (50%) or more of the shares of stock entitled to vote
for the election of directors, in the case of a corporation, (c) fifty percent
(50%) or more of the equity or controlling interests in the case of any other
type of legal entity (including, without limitation, joint ventures) or status
as a general partner in any partnership, or (d) any other arrangement whereby a
party controls or has the right to control the Board of Directors or equivalent
governing body of an entity.

     1.4 "Agreement" has the meaning set forth in the preamble.

     1.5 "API" means active pharmaceutical ingredient.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


<PAGE>

     1.6 "Applicable Law" means applicable United States and foreign laws,
rules, regulations, guidelines and standards, including, but not limited to,
those of the FDA and comparable foreign Regulatory Authorities, including
without limitation the Act.

     1.7 "Aventis" means Sanofi Aventis or any of its Affiliates.

     1.8 "Branded Product" means the capsule formulation pharmaceutical product
containing the active ingredient Ramipril as approved by the FDA under New Drug
Application Number 19-901 and marketed by King under the name Altace.

     1.9 "Bulk Product" means Ramipril in a form intended for further processing
into a pharmaceutical formulation and which is not in final formulation intended
for use by consumers.

     1.10 "Calendar Quarter" means the period of three (3) consecutive calendar
months ending on each March 31, June 30, September 30 or December 31, as the
case may be, of a year; provided that the first Calendar Quarter of an agreement
will begin on the Effective Date and end on the last day of the calendar quarter
within which the Effective Date falls.

     1.11 "Capsule Supply Agreement" has the meaning set forth in Section 3.13.

     1.12 "cGMP" means the minimum standards for methods to be used in, and the
facilities or controls to be used for, the manufacture, processing, packing or
holding of a drug to assure that such drug meets the requirements of the Act as
to safety, and has the identity and strength and meets the quality and purity
characteristics that it purports or is represented to possess, as established
through FDA regulations (including, but not limited to, 21 C.F.R. Parts
210-211), FDA guidance and FDA current review and inspection standards and
current industry standards.

     1.13 "Cobalt" has the meaning set forth in the preamble.

     1.14 "Confidential Information" means the existence and contents of this
Agreement and any information, in whatever form, disclosed by a Party or its
Affiliates (the "Disclosing Party"), to the other Party or its Affiliates (the
"Receiving Party"), in connection with the performance or implementation of this
Agreement including, but not limited to, the Specification, the Branded Product,
the Ramipril drug master file, including without limitation any pending patent
applications, patent office correspondence, FDA applications and submissions,
FDA correspondence, technical or clinical data, trade secrets, and know-how,
including, but not limited to research, product plans, products, services,
suppliers, customer lists and customers, prices and costs, markets, software,
developments, ideas, techniques, business methods, photographs,
sound-recordings, algorithms, inventions, laboratory notebooks, processes,
formulas, technology, specifications, test results, designs, drawings,
engineering, hardware configuration information, marketing, licenses, finances,
budgets and other actual or anticipated business, research or development
information or any information provided pursuant to Sections 3.7 and 3.9 through
3.11 of this Agreement which is disclosed by the Disclosing Party to the
Receiving Party, whether or not specifically designated as confidential.
Confidential Information will not include:

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       2

<PAGE>

          (a) information which at the time of disclosure is publicly known;

          (b) information which, after the time of disclosure, becomes part of
the public domain, except by breach of an agreement between the Disclosing Party
or any Affiliate thereof and the Receiving Party or any Affiliate thereof;

          (c) information which is or was in the possession of the Receiving
Party or any Affiliate thereof at the time of disclosure by the Disclosing Party
and was not acquired directly or indirectly from the Disclosing Party or any
Affiliate thereof or from any other party under an agreement of confidentiality
to the Disclosing Party or any Affiliate thereof; and

          (d) information which the Receiving Party can show through written
documentation is or was developed by the Receiving Party or its Affiliates
independently of receipt hereunder.

     1.15 "Dispute" has the meaning set forth in Section 7.6.

     1.16 "Effective Date" has the meaning set forth in the preamble.

     1.17 "FDA" means the United States Food and Drug Administration or any
successor organization and all agencies under their direct control.

     1.18 "Generic Product" means an unbranded version of the Branded Product,
with trade dress, including, without limitation, product intaglio that differs
from the Branded Product.

     1.19 "Indemnitee" has the meaning set forth in Section 4.4(c).

     1.20 "Indemnitor" has the meaning set forth in Section 4.4(c).

     1.21 "Initial Forecast" has the meaning set forth in Section 3.2(a).

     1.22 "Initial Term" has the meaning set forth in Section 6.1.

     1.23 "King" has the meaning set forth in the preamble.

     1.24 "Launch Date" has the meaning set forth in Section 2.5(a).

     1.25 "Launch Quantity" has the meaning set forth in Section 3.2(a).

     1.26 "Party" or "Parties" has the meaning set forth in the preamble.

     1.27 "Ramipril" means the compound (2S,3aS,6aS)-1[(S)-N-[(S)-1-Carboxy-
3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl
ester.

     1.28 "Regulatory Authority" means the FDA or any counterpart of the FDA
outside the United States, or other national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity with authority over the distribution, importation,
exportation, manufacture, production, use, storage, transport, clinical

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       3

<PAGE>

testing, pricing and/or sale of the Generic Product, including any device
incorporating the Generic Product.

     1.29 "Renewal Term" has the meaning set forth in Section 6.1.

     1.30 "Specifications" means the specifications provided by King with
respect to the Branded Product, as approved by applicable Regulatory Authorities
and mandated by Applicable Law, as amended from time to time in accordance with
such standards.

     1.31 "Term" has the meaning set forth in Section 6.1.

     1.32 "Territory" means the United States.

     1.33 "Third Party" means any person other than a Party or an Affiliate of a
Party.

2.   DISTRIBUTION; LAUNCH

     2.1 Generic Product. King hereby grants to Cobalt the non-exclusive,
personal, non-transferable (provided that Cobalt will have the right to transfer
the right set forth in this Section 2.1 to Cobalt Laboratories, Inc.), and
non-assignable right to distribute the Generic Product in the Territory during
the Term in accordance with the terms hereof. The foregoing right will not
include any right whatsoever to (a) any intellectual property owned or licensed
by King or Aventis, including, without limitation, any right to use the
trademark Altace or (b) the New Drug Application Number 19-901, nor will it
include the right to distribute the Generic Product outside the Territory or
manufacture the Generic Product or have the Generic Product manufactured at any
time.

     2.2 Distribution of the Generic Product. Cobalt may distribute the Generic
Product in the Territory through distributors and wholesalers in a manner
customary for the sale and distribution of generic pharmaceutical products,
including, without limitation, communicating and interacting with, and making
information available to, distributors and wholesalers concerning the Generic
Product; provided, however, that Cobalt will not promote the Generic Product in
the Territory in any manner; and provided further that (a) any such distributor
will be required to enter into a written agreement with Cobalt agreeing to
comply with the terms of this Agreement, and (b) Cobalt has obtained King's
prior approval of such distributor and the terms of the relevant written
agreement, which approval will not be unreasonably withheld or delayed.

     2.3 King's Rights to Branded Product. Nothing contained in this Agreement
will prevent King from marketing, distributing, selling and promoting the
Branded Product in the Territory during the Term.

     2.4 Cobalt Obligations. Cobalt will use commercially reasonable efforts to
launch and distribute the Generic Product as of the Launch Date, such efforts to
be no less than the efforts made by Cobalt in connection with other generic
products distributed by Cobalt.

     2.5 Launch Timing.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       4

<PAGE>

          (a) King and Cobalt agree that the Generic Product may only be
commercially launched by Cobalt upon the earlier of (1) [***], the "Launch
Date").

          (b) Prior to the Launch Date, King will supply Cobalt with an agreed
upon Launch Quantity; provided that neither Cobalt nor any of its Affiliates may
distribute such Launch Quantity prior to the Launch Date, and all wholesalers
and distributors will hold the Launch Quantity in quarantine until the Launch
Date and may not distribute it until they receive written authorization from
Cobalt. If this Agreement is terminated prior to the Launch Date, then Cobalt
will return the Launch Quantity to King.

3.   SUPPLY

     3.1 Purchase of Generic Product. During the Term, subject to Section 3.13,
Cobalt will purchase [***] the Generic Product in finished form from King, and
King or a designee of King, will manufacture, sell and deliver to Cobalt such
quantities of Generic Product [***], in accordance with the terms and conditions
set forth in this Article 3 and this Agreement.

     3.2 Forecasts; Purchase Orders.

          (a) At least [***] prior to the anticipated Launch Date, or as soon as
practicable after Cobalt provides notice to King of the anticipated Launch Date,
Cobalt will deliver to King a [***] forecast for its purchases of Generic
Product beginning on the date of such forecast (the "Initial Forecast"), which
will include an initial launch quantity agreed upon by the Parties (the "Launch
Quantity"). The first [***] included in such Initial Forecast will constitute a
binding order for Generic Product from King. Thereafter, Cobalt will provide
King with rolling [***] forecasts for the Generic Product on a quarterly basis
within [***] prior to the start of each Calendar Quarter covering Cobalt's
expected purchases of Generic Product during the [***] commencing at the
beginning of such upcoming Calendar Quarter. The forecast for the first [***]
included in each rolling forecast (except for the Initial Forecast) will
constitute a binding order from Cobalt for [***] the Generic Product included in
such forecast, and the forecast for the subsequent [***] included in each
rolling forecast (except for the Initial Forecast) will constitute a binding
order from Cobalt for [***] the Generic Product included in such forecast.

          (b) Cobalt will place purchase orders for Generic Product in
accordance with its binding forecasts by delivering a purchase order in writing
to King no later than the 25th day of each calendar month. Each purchase order
will contain the information set forth in Appendix 1 to this Agreement. Each
purchase order will be for at least the minimum quantities consistent with
King's then current minimum batch sizes for the Branded Product or multiples
thereof. In the event of a conflict between the terms and conditions of this
Agreement and a purchase order, the terms and conditions of this Agreement will
control.

          (c) No purchase order will be binding on King unless accepted in
writing by King, with confirmation of the expected delivery date for the Generic
Product included in the purchase order. King will use commercially reasonable
efforts to accept the purchase order as presented and confirm date of shipment
within [***] of receipt thereof; provided that King will not be required to
accept purchase orders (i) for quantities of Generic Product in excess of the

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       5

<PAGE>

amount specified in the forecast for the relevant month, (ii) if the delivery
lead time for the purchase order is less than [***], or (iii) if it otherwise
fails to comply with the terms and conditions of this Agreement.

     3.3 Delivery.

          (a) King will deliver the Generic Product to Cobalt or Cobalt's US
designee FOB King's or King's designee's manufacturing or packaging site or
warehouse. Title and risk of loss as to the Generic Product purchased by Cobalt
will pass to Cobalt upon the earlier of (i) a common carrier accepting
possession or control of such Generic Product and (ii) the passage of such
Generic Product from the loading dock of King's or King's designee's site or
warehouse to any employee, agent or contractor of Cobalt or such common carrier.

          (b) Each delivery will be accompanied by a certificate of analysis
containing such information as may be agreed upon by King and Cobalt from time
to.

          (c) At [***] expense, King will ship the Generic Product on a carrier
or carriers specified by Cobalt under the designated procedures provided by
Cobalt for transportation of the Generic Product. The [***] freight, insurance,
handling, fees, taxes and other costs associated with the shipment of the
Generic Product will be borne by [***]. King and Cobalt agree to cooperate to
prepare, obtain, and maintain all necessary export and import registrations
relating to the Generic Product. The [***] export licenses, import licenses and
customs formalities for the import and export of goods will be [***].

     3.4 Capacity. If King, upon receiving a forecast or purchase order in
accordance with Section 3.2, believes that it will be unable to meet such
forecast or purchase order, King will give written notice of such inability to
Cobalt. King will use commercially reasonable efforts to deliver Generic Product
to Cobalt in accordance with any purchase order accepted by King as set forth in
Section 3.2. King will not be liable to Cobalt for any late delivery of Generic
Product if King has satisfied its obligation set forth in the preceding
sentence.

     3.5 King's Source. King will have the right, in its sole discretion, to
purchase from any Third Party, including Aventis, the Generic Product or Bulk
Product used to manufacture the Generic Product sold to Cobalt during the Term.

     3.6 Price and Payments. Cobalt will pay to King a price per unit for the
Generic Product fixed at a gross margin acceptable to King in its sole
discretion, but such price will not exceed [***] of the wholesale acquisition
cost per unit of the Branded Product at time of purchase of the Generic Product.
King will submit invoices to Cobalt for Generic Product delivered to Cobalt from
time to time. Cobalt will make all payments to King in United States Dollars
within [***] after the date of each invoice. Interest will be payable upon all
amounts not paid on the due date at the rate of [***] over the base rate of
interest reported in the Wall Street Journal, New York edition on the date of
payment by Cobalt to King and will accrue from the due date until such sum is
paid, whether before or after judgment.

     3.7 Shortcomings and Defects.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       6

<PAGE>

          (a) Within [***] after the delivery of Generic Product to Cobalt,
Cobalt will notify King in writing of any complaint regarding obvious
qualitative faults and/or quantitative shortcomings in the Generic Product, and
Cobalt will simultaneously send samples of faulty Generic Product to King. If
Cobalt fails to notify King of any such defect within such [***] period, Cobalt
will be deemed to have accepted the delivered Generic Product with respect to
such obvious faults or shortcomings. Cobalt will notify King in writing within
[***] after becoming aware of any defects in the Generic Product that may not or
would not have been obvious at delivery by visual inspection of such Generic
Product made with reasonable care, and Cobalt will simultaneously send samples
of faulty Generic Product to King.

          (b) If King agrees that such Generic Product is defective or the
Generic Product has been confirmed to be defective by an independent party
pursuant to this Section 3.7, King will replace any defective Generic Product
with respect to which Cobalt has notified King as set forth in this Section 3.7
[***] at the next practicable delivery date.

          (c) If King disagrees that the Generic Product is defective, the
Parties will endeavor to settle such disagreement amicably and constructively
between themselves. If they fail to agree within [***] after receipt of the
notice of defect, the Parties agree to nominate an independent, reputable
laboratory within the Territory, acceptable to both Parties, which will examine
representative samples taken from such consignment using the methods of analysis
provided by the Parties, and the result will be binding upon the Parties. The
charges for such examination will be borne by the Party found to be in error
with respect to whether or not the Generic Product is defective.

          (d) King's [***] liability or responsibility for defective Generic
Product will be limited to right of replacement set forth in this Section 3.7.
Cobalt will make arrangements with King for the return or disposal of any
Generic Product rejected in accordance with this Section 3.7; the costs of such
return or disposal will be paid by King.

     3.8 Labeling. King will use, or cause its manufacturer to use, the
appropriate packaging art, packaging, and labeling provided by Cobalt for the
Generic Product; provided that King has approved in writing all packaging art,
labeling, and all packaging provided by Cobalt; and provided further that such
art, packaging, and labeling comply with Applicable Law. Cobalt will provide
King with camera-ready proofs of all packaging materials and labeling. All
packaging and trade dress of the Generic Product, including, without limitation,
product intaglio must differ from the Branded Product.

     3.9 Recalls.

          (a) Cobalt will comply, and assist King as appropriate in complying,
with recall policies regarding the Branded Product or Generic Product issued
from time to time by King or any applicable Regulatory Authority and
communicated to King. King will have [***] authority to communicate with any
Regulatory Authorities regarding any recall of the Generic Product, as King
believes necessary [***].

          (b) Cobalt will bear the expense of any recall resulting from (1)
damages to or defects in the Generic Product occurring after delivery of such
Generic Product, (2) packaging or

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       7

<PAGE>

labeling of the Generic Product, including any infringement claims regarding any
trademarks, trade names or trade dress used with the Generic Product, (3)
Cobalt's actions or inactions as a seller or distributor of the Generic Product,
or (4) Cobalt's or its Affiliates' negligence or willful misconduct. King will
bear the expense of any recall resulting from King's or King's designee's
manufacturing actions with respect to the Generic Product.

          (c) For purposes of this Section 3.9, expenses of recall include,
without limitation, the cost of replacement of any recalled Generic Product and
expenses of notification, destruction, or return of the recalled Generic
Product.

     3.10 Regulatory Compliance; Access to Facilities.

          (a) King will advise Cobalt promptly if an authorized agent of a
Regulatory Authority visits, or if King receives notice that a Regulatory
Authority plans to visit, the facilities where the Generic Product is
manufactured. King will furnish to Cobalt all material information supplied to,
or supplied by, any Regulatory Authority, including the form 483 observations
and responses, to the extent that such report relates to the Generic Product, or
the ability of King to supply such Generic Product, within [***] of King's
receipt of such information or delivery of such information, as the case may be.
To the extent allowable under Applicable Law, before King responds to any
Regulatory Authority, Cobalt will have the right to review and approve such
final response, such approval not to be unreasonably withheld or delayed.

          (b) Upon the reasonable prior written request of Cobalt, Cobalt will
have the right to inspect those portions of the manufacturing, storage and
testing facilities of King where the Generic Product is being manufactured,
stored or tested, as the case may be, during regular business hours and without
undue interference to King's business operations to ascertain compliance with
cGMP and any agreed-upon Specifications, such inspections to be held no more
than once per year unless additional inspections are agreed upon by the Parties.

     3.11 Product Complaints or Adverse Drug Events. Each Party will promptly
submit to the other Party all Generic Product safety and efficacy inquiries,
Generic Product quality complaints and adverse drug event reports received by
such Party or any Affiliate of such Party, together with all available evidence
and other information relating thereto. Except as otherwise required by
Applicable Law, [***] will be responsible for investigating and responding to
all such inquiries, complaints and adverse events reports regarding the Generic
Product with the inquiring, complaining or reporting party. [***] will be
responsible for any and all interactions with any Regulatory Authority relating
to any such inquiries, complaints or reports as [***] necessary, [***].

     3.12 Defense of Claims.

          (a) If any action, suit or proceeding is brought against King, Cobalt
or either of their Affiliates alleging infringement or misappropriation of the
intellectual property rights of a Third Party by reason of any Party's actions
taken pursuant to this Agreement (an "Action"), King will have the first right
to defend, [***], any such Action; provided that King will provide prior notice
of such Action to Cobalt, and King will consult with Cobalt concerning such
Action. Cobalt will join any such Action as a party if reasonably requested to
do so by King, and Cobalt

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       8

<PAGE>

hereby consents to jurisdiction and venue of any such Action if King names
Cobalt as a party thereto. King will have full control over the conduct of any
such Action; provided that Cobalt will have the right to provide comments
concerning such Action to King, which King will consider in good faith. King
will give Cobalt prior notice of any consent to entry of judgment or settlement
of such Action.

          (b) If King fails to exercise its first right to defend such Action
within [***] after receipt of the notice of such Action, then Cobalt will be
entitled to defend such Action [***]; provided that Cobalt will provide prior
notice of such its defense of such Action to King, and Cobalt will consult with
King concerning such Action. King will join any such Action as a party if
reasonably requested to do so by Cobalt, and King hereby consents to
jurisdiction and venue of any such Action if Cobalt names King as a party
thereto. Cobalt will have full control over the conduct of any such Action;
provided that King will have the right to provide comments concerning such
Action to Cobalt, which Cobalt will consider in good faith. Cobalt will give
King prior notice of any consent to entry of judgment or settlement of such
Action.

          (c) In any event, King and Cobalt will assist one another and
cooperate with one another in any such Action at the other Party's request
without expense to the requesting Party. The Parties will each bear [***] costs
and expenses associated with any litigation or settlement costs thereof, and
each will [***] share all damages, royalties or other amounts granted or awarded
to any Third Party as a result of an Action.

     3.13 [***] Agreement. Following the Effective Date, King and Cobalt will
negotiate in good faith to enter into [***] agreement (the "[***] Agreement")
pursuant to which Cobalt, or one of its Affiliates, will [***] beginning on a
date [***] and set forth in the [***] Agreement. [***] Agreement will provide
that [***] during the period in which [***].

4.   REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION

     4.1 Representations and Warranties of King.

          (a) Corporate Power. King is organized and validly existing under the
laws of the State of Tennessee and has full corporate power and authority to
enter into this Agreement and to carry out the provisions hereof.

          (b) Due Authorization. King is duly authorized to execute and deliver
this Agreement and to perform its obligations hereunder.

          (c) Binding Agreement. This Agreement is a legal and valid obligation
binding upon King and enforceable in accordance with their terms. The execution,
delivery and

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       9

<PAGE>

performance of this Agreement by King does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which
it may be bound, nor violate any material law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.

          (d) Aventis Agreements. Cobalt may exercise its rights and perform its
obligations hereunder, in accordance with the terms and conditions of this
Agreement without violating the terms of King's or its Affiliates' pre-existing
agreements with Aventis or its Affiliates and without infringing or
misappropriating the intellectual property of Aventis or its Affiliates that is
licensed to King or its Affiliates under its pre-existing agreements with
Aventis or its Affiliates.

          (e) Generic Product. Generic Product manufactured by King or King's
designee and sold to Cobalt pursuant to this Agreement (i) will be manufactured
in conformity with cGMP, (ii) will meet, in all material respects at the time of
delivery to the common carrier, the Specifications in effect at the time of
manufacture, (iii) at the time of delivery to the common carrier, will not be
adulterated within the meaning of the Act and will not be an article that may
not, under the provisions of the Act, be introduced into interstate commerce,
and (iv) will be free and clear of all liens, security interests and other
encumbrances at the time of delivery to the common carrier. During the term of
this Agreement, King and King's designee will comply in all material respects
with all Applicable Laws with respect to the performance of King's obligations
under this Agreement.

     4.2 Representations and Warranties of Cobalt.

          (a) Corporate Power. Cobalt is organized and validly existing under
the laws of the State of Georgia and has full corporate power and authority to
enter into this Agreement and to carry out the provisions hereof.

          (b) Due Authorization. Cobalt is duly authorized to execute and
deliver this Agreement and to perform its obligations hereunder.

          (c) Binding Agreement. This Agreement is a legal and valid obligation
binding upon Cobalt and enforceable in accordance with its terms. The execution,
delivery and performance of this Agreement by Cobalt does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a party
or by which it may be bound, nor violate any material law or regulation of any
court, governmental body or administrative or other agency having jurisdiction
over it.

          (d) FDA Debarment. As of the Effective Date, none of Cobalt, its
Affiliates, or any of their respective employees or agents, in their capacity as
such, have been disqualified or debarred by the FDA, pursuant to 21 U.S.C.
Sections 335(a) or (b), or been charged with or convicted under United States
law for conduct relating to the development or approval, or otherwise relating
to the regulation of any Generic Product under the Generic Drug Enforcement Act
of 1992, or any other relevant law, rule, or regulation or been disbarred,
disqualified, or convicted under or for any equivalent or similar applicable
foreign law, rule, or regulation.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       10

<PAGE>

     4.3 Disclaimer; Limitations. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, THE PRECEDING REPRESENTATIONS AND WARRANTIES ARE THE PARTIES' ONLY
REPRESENTATIONS AND WARRANTIES CONCERNING THE GENERIC PRODUCT AND ARE MADE
EXPRESSLY IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE,
MERCHANTABILITY, NONINFRINGEMENT OR OTHERWISE. EXCEPT AS MAY ARISE FROM DAMAGES
OCCASIONED BY THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY OR A PARTY'S
OBLIGATIONS UNDER SECTION 4.4, NEITHER PARTY NOR ANY AFFILIATE WILL BE LIABLE
FOR ANY INDIRECT, SPECIAL, PUNITIVE, EXEMPLARY, OR CONSEQUENTIAL DAMAGES ARISING
FROM THIS AGREEMENT OR FOR ANY AMOUNTS REPRESENTING LOSS OF PROFITS OR LOSS OF
BUSINESS, WHETHER THE BASIS OF THE LIABILITY IS BREACH OF CONTRACT, TORT,
STATUTES, OR ANY OTHER LEGAL THEORY.

     4.4 Indemnification.

          (a) Indemnification by Cobalt. Cobalt agrees to defend, indemnify and
hold harmless King, its Affiliates, and their respective directors, employees
and agents from and against [***] claims, liabilities, damage, costs or expenses
(including any liability arising out of the injury or death of any person or
damage to any property and including reasonable attorney's fees) resulting from
[***] claim by a Third Party, arising out of or relating to (i) the willful
misconduct or negligence of Cobalt or any of its Affiliates; (ii) any material
misrepresentation or breach of warranty of Cobalt contained in this Agreement by
Cobalt or any of its Affiliates; (iii) any material breach of any covenant or
obligation of Cobalt contained in this Agreement by Cobalt or any of its
Affiliates; or (iv) the sale, marketing, distribution, or manufacture of the
Generic Product by Cobalt or any of its Affiliates, including, without
limitation, any product liability claims and any infringement claims regarding
any trademarks, trade names or trade dress used with the Generic Product, except
to the extent that King is obligated to indemnify Cobalt for such claim pursuant
to Section 4.4(b).

          (b) Indemnification by King. King agrees to defend, indemnify and hold
harmless Cobalt, Cobalt's Affiliates, and their respective directors, employees
and agents from and against [***] claims, liabilities, damage, costs or expenses
(including any liability arising out of the injury or death of any person or
damage to any property and including reasonable attorney's fees) resulting from
[***] claim by a Third Party, arising out of or relating to (i) the willful
misconduct or negligence of King or any of its Affiliates; (ii) any material
misrepresentation or breach of warranty of King contained in this Agreement by
King or any of its Affiliates; or (iii) any material breach of any covenant or
obligation of King contained in this Agreement.

          (c) Indemnification Procedure. A party (the "Indemnitee") that intends
to claim indemnification under this Section 4.4 will notify the indemnifying
party (the "Indemnitor") within a reasonable time in writing of any action,
claim, or liability in respect of which the Indemnitee believes it is entitled
to claim indemnification from the Indemnitor; provided that the failure to give
timely notice to the Indemnitor will not release the Indemnitor from any
liability to the Indemnitee except to the extent the Indemnitor is actually
prejudiced

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       11

<PAGE>

thereby. The Indemnitor will have the right, by notice to the Indemnitee, to
assume the defense of any such action or claim within the fifteen (15)-day
period after the Indemnitor's receipt of notice of any action or claim with
counsel of the Indemnitor's choice and at the sole cost of the Indemnitor. If
the Indemnitor does not so assume the defense of such Third Party claim, the
Indemnitee may assume such defense with counsel of its choice and at the sole
cost of the Indemnitor. If the Indemnitor so assumes such defense, the
Indemnitee may participate therein through counsel of its choice, but at the
sole cost of the Indemnitee. The party not assuming the defense of any such
claim will render all reasonable assistance to the party assuming such defense,
and all reasonable out-of-pocket costs of such assistance will be for the
account of the Indemnitor. No such claim will be settled other than by the party
defending the same, and then only with the consent of the other party, which
will not be unreasonably withheld; provided that the Indemnitee will have no
obligation to consent to any settlement of any such action or claim that imposes
on the Indemnitee any liability or obligation that cannot be assumed and
performed in full by the Indemnitor, and the Indemnitee will have no right to
withhold its consent to any settlement of any such action or claim if the
settlement involves only the payment of money by the Indemnitor or its insurer.

     4.5 Distribution/Product Liability Insurance. Beginning on the Launch Date,
both Parties will obtain and maintain in effect, for the term of this Agreement
and for a period of five (5) years thereafter, liability insurance or indemnity
policies, in an amount not less than ten million USD ($10,000,000) in the
aggregate with an indemnity to principals clause with respect to products
liability and distribution. Such policies will be blanket policies and will
insure against liability on the part of the Parties and their Affiliates, as
their interests may appear, due to injury, disability or death of any person or
persons, or injury to property, arising from the distribution of Generic
Product. Beginning on the Launch Date and thereafter on January 1 of each year
during the term of this Agreement, each Party will provide to the other a copy
of its certificate of insurance (i) summarizing the insurance coverage and (ii)
identifying any exclusions. Each Party will promptly notify the other of any
material adverse alterations to the terms of this policy or decreases in the
amounts for which insurance is provided.

     4.6 Product Liability Claims. As soon as it becomes aware, each Party will
give the other prompt written notice of any defect or alleged defect in any
Generic Product, any injury alleged to have occurred as a result of the use or
application of the Generic Product, and any circumstances that may give rise to
litigation or recall of the Generic Product or regulatory action that may affect
the sale or manufacture of the Generic Product, specifying, to the extent the
Party has such information, the time, place and circumstances thereof and the
names and addresses of the persons involved. Each Party will also furnish
promptly to the other copies of all papers received in respect of any claim,
action or suit arising out of such alleged defect, injury or regulatory action.

5.   CONFIDENTIALITY

     5.1 Confidentiality. All Confidential Information provided by the
Disclosing Party to the Receiving Party in connection with this Agreement is
proprietary to the Disclosing Party and will be maintained in strict confidence
by the Receiving Party. Such Confidential Information will remain the property
of the Disclosing Party, and the Receiving Party will not use the same for or on
behalf of any entity other than the Disclosing Party. At the termination of this

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       12

<PAGE>

Agreement, the Parties will promptly return to the Disclosing Party any physical
embodiments (including copies) of any such Confidential Information or, at the
Disclosing Party's sole election, destroy the same under the Disclosing Party's
supervision.

     5.2 Disclosure. Nothing in this Agreement will be construed as preventing
or in any way inhibiting either Party from disclosing Confidential Information
necessary to comply with applicable laws. In the event a Party will deem it
reasonably necessary to disclose Confidential Information belonging to the other
Party pursuant to this Section 5.2, the Disclosing Party will to the extent
possible give reasonable advance notice of such disclosure to the other Party,
and will consider in good faith the other Party's objections to such disclosure,
including suggestions to redact Confidential Information, and take reasonable
measures to ensure confidential treatment of such information.

     5.3 Period of Obligation. This Article will survive expiration or
termination of this Agreement for a period of [***] from the Effective Date.

     5.4 Equitable Relief. Cobalt and King each acknowledges that a breach by it
of Article 5 cannot reasonably or adequately be compensated in damages in an
action at law and that such a breach may cause the other Party irreparable
injury and damage. By reason thereof, each Party agrees that the other Party may
be entitled, in addition to any other remedies it may have under this Agreement
or otherwise, to preliminary and permanent injunctive and other equitable relief
to prevent or curtail any breach of Article 5 by the other Party; provided,
however, that no specification in this Agreement of a specific legal or
equitable remedy will be construed as a waiver or prohibition against the
pursuing of other legal or equitable remedies in the event of such a breach.
Each Party agrees that the existence of any claim, demand, or cause of action of
it against the other Party, whether predicated upon this Agreement, or
otherwise, will not constitute a defense to the enforcement by the other Party,
or its successors or assigns, of the covenants contained in Article 5.

6.   TERM AND TERMINATION

     6.1 Term. Unless earlier terminated as set forth in Section 6.2 or 6.3,
this Agreement will commence on the Effective Date and will continue for an
initial term of six (6) months (the "Initial Term"). Thereafter, this Agreement
will automatically renew for consecutive periods of six (6) months (each a
"Renewal Term" and, together with the Initial Term, the "Term") unless and until
either Party provides the other Party written notice of its intention not to
renew at least ninety (90) days prior to the end of the then-current term.

     6.2 Termination. This Agreement may only be terminated upon mutual written
agreement of Cobalt and King or upon three (3) months' prior written notice if
one Party is in material breach of this Agreement and fails to cure that breach
within such three (3)-month period.

     6.3 Termination for Bankruptcy. This Agreement may be canceled upon fifteen
(15) days' prior written notice by either Party at any time during this
Agreement if: (a) the other Party will file in any court, pursuant to any
statute of any government in any country, a petition in bankruptcy or insolvency
or for reorganization, or for an arrangement or for the appointment of a

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       13

<PAGE>

receiver or trustee of the Party or of its assets; (b) any other Party proposes
a written agreement of composition for extension of its debts; (c) the other
Party will be served with an involuntary petition against it, filed in any
insolvency proceeding, and such petition will not be dismissed within sixty (60)
days after filing thereof; (d) the other Party will be a Party to any
dissolution or liquidation; (e) the other Party will make a general assignment
for the benefit of its creditors; or (f) if the other Party is subject to any
final order of debarment which can be expected to have a material adverse effect
on the commercialization of Generic Product. A termination pursuant to this
Section 6.3 will constitute a termination for material breach, and the
non-breaching party will be entitled to seek damages or equitable relief for
such material breach.

     6.4 Accrued Obligations. Any termination of this Agreement for any reason
does not relieve any Party of any obligation or liability accrued prior to the
termination or rescind anything done by any Party, and the termination does not
affect in any manner any rights of any Party arising under this Agreement prior
to the termination.

     6.5 Survival. The terms of Sections 3.6 (as may relate to any unpaid
amounts due and owing), 3.9, 3.10, 3.11, 7.1, 7.5, 7.6, 7.7, 7.9 and 7.10 and
Articles 4, 5 and 6 will survive any expiration or termination of this
Agreement.

7.   MISCELLANEOUS

     7.1 Public Announcements. Cobalt and its Affiliates will not make any
publicity releases, interviews, or other dissemination of information concerning
this Agreement or its terms, or either Party's or its Affiliates' performance
hereunder, to communication media, financial analysts, or others without the
approval of King, which approval will not unreasonably be withheld. King and its
Affiliates will not make any publicity releases, interviews, or other
dissemination of information concerning this Agreement or its terms, or either
Party's or its Affiliate's performance hereunder, to communication media,
financial analysts, or others without providing prior notice to Cobalt. Either
Party may upon notice to the other Party make any disclosure in filings with
regulatory agencies as required by law or applicable court order; provided that
the other Party and its Affiliates will have the opportunity to consult in
advance on such disclosures and filings.

     7.2 Force Majeure. Neither Party nor any Affiliate thereof will be liable
for any default or delay in such Party's or any Affiliate's performance if such
default or delay is caused by an event beyond the reasonable control of such
Party or Affiliate, including, but not limited to: act of God; war or
insurrection; civil commotion; destruction of essential facilities or materials
by earthquake, fire, flood or storm; labor disturbance; epidemic; or other
similar event; provided, however, that the Party or Affiliate so affected will
give prompt notice of such event, and will use its commercially reasonable
efforts to avoid, remove or alleviate such causes of nonperformance and will
continue performance hereunder with the utmost dispatch whenever such causes are
removed.

     7.3 Entire Agreement. This Agreement and the documents referred to herein,
including without limitation any Appendices hereto (which are hereby
incorporated by reference), constitute the entire agreement between the Parties
and the Affiliates of each pertaining to the subject matter hereof, and this
Agreement supersedes, on its Effective Date, any

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       14

<PAGE>

other agreements, understandings, promises and representation, whether written
or oral, between the Parties and such Affiliates relating to the same subject
matter save for where otherwise expressed in this Agreement. No agent of either
Party or any Affiliate of either is authorized to make any representation,
promise, or warranty not contained in this Agreement.

     7.4 Amendment and Waiver. This Agreement may only be amended by the Parties
in writing, making specific reference to this Agreement; provided that the same
is signed by all Parties. No course of dealing between the Parties any their
Affiliates or failure by either Party or any Affiliates thereof to exercise any
right or remedy hereunder will constitute an amendment to this Agreement or a
waiver of any other right or remedy or the later exercise of any right or
remedy.

     7.5 Governing Law. This Agreement will be construed in accordance with the
laws of the State of New York, without regard to any choice of law provisions.
Each Party and each Affiliate of each Party hereby submits itself for the sole
purpose of this Agreement and any controversy arising hereunder to the
jurisdiction of the courts located in the Southern District of New York and any
courts of appeal therefrom, and waives any objection on the grounds of lack of
jurisdiction (forum non conveniens or otherwise) to the exercise of such
jurisdiction over it by any such courts.

     7.6 Dispute Resolution. Any controversy, claim, or dispute arising out of
or relating to this Agreement (collectively, a "Dispute") will be attempted to
be settled by the Parties and their Affiliates, in good faith. In the event that
there is no resolution of such Dispute, it will further be submitted to
appropriate senior management representatives of each Party in a good faith
effort to effect a mutually acceptable resolution thereof. Only if such efforts
are not successful will such Dispute be resolved by binding arbitration. Such
arbitration will take place in New York, New York and it will proceed in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association. Within [***] from the filing of the demand or submission, or longer
if the Parties agree, Cobalt and King will each select one arbitrator; the two
arbitrators so appointed will select and appoint a third neutral arbitrator.
Judgment upon the award rendered by arbitration will be binding and may be
entered in any court having jurisdiction thereof. Costs of arbitration are to be
divided by the Parties in the following manner: Cobalt will pay [***], King will
pay [***], Cobalt and King will [***], and each will [***].

     7.7 Assignment. Cobalt may not assign any right or obligation hereunder,
except as provided in Section 2.1. King may not assign any right or obligation
hereunder without the written consent of Cobalt, such consent not to be
unreasonably withheld; provided that King may assign this Agreement and the
rights, obligations, and interests of King, in whole or in part, to any of its
Affiliates (for so long as they remain Affiliates) or to any Third Party that
succeeds to all or substantially all of King's business or assets relating to
this Agreement, whether by sale, merger, operation of law, or otherwise, or to
one or more financial institutions providing financing to King, pursuant to the
terms of the relevant security agreement, and, upon the occurrence of any such
succession, will make such assignment; provided that such assignee or transferee
promptly agrees in writing to be bound by the terms and conditions of this
Agreement. This Agreement will be binding upon and inure to the benefit of the
Parties hereto and their respective successors and assigns. Any attempted
assignment in violation of this provision will be void and of no effect.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       15

<PAGE>

     7.8 Nature of Agreement. In operating under the Agreement, each Party will
act independently and this Agreement will not be construed as creating any
partnership, joint venture or incorporated business entity. Neither Party will
have any authority to incur any liability or obligation whatsoever on behalf of
the other.

     7.9 Notice. Any notice, demand, waiver, consent, approval or other
communication which is required or permitted to be given to any Party under this
Agreement will be in writing, will specifically refer to this Agreement, and
will be effective on receipt, as evidenced in writing, when given by registered
airmail or certified mail, postage prepaid, or overnight courier, and addressed,
unless otherwise specified in writing, to the addresses of the Parties described
below, and effective upon sending if sent by facsimile confirmed by a written
transmission report:

                    If to King:

                    501 Fifth Street
                    Bristol, TN 37620
                    Fax: 423-990-2566
                    Attention: General Counsel

                    copy to:

                    Jones Day
                    222 East 41st Street
                    New York, NY 10017
                    Fax: 212-755-7306
                    Attention: F. Dominic Cerrito, Esq.

                    If to Cobalt:

                    6500 Kitimat Road
                    Mississauga, Ontario  LN5 2Bb
                    Fax: 905-363-0306
                    Attention: Ian Jacobsen

                    copy to:

                    Foley & Lardner LLP
                    3000 K Street, N.W.
                    Washington, DC 20007
                    Fax: 202-672-3465
                    Attention: Steven A. Maddox
                               Douglas H. Carsten

     7.10 Severability.

          (a) In the event any portion of this Agreement will be held illegal,
void or ineffective, the remaining portions hereof will remain in full force and
effect.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       16

<PAGE>

          (b) If any of the terms or provisions of this Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions will be deemed inoperative to the extent that they may conflict
therewith and will be deemed to be modified to conform with such statute or rule
of law, and the remaining portions hereof will remain in full force and effect.

          (c) In the event that the terms and conditions of this Agreement are
materially altered as a result of Section 7.10(a) or 7.10(b), the Parties will
renegotiate the terms and conditions of this Agreement to resolve any
inequities.

     7.11 Execution in Counterparts. This Agreement may be executed in two or
more counterparts, each of which will be an original and all of which will
constitute together the same instrument.

     7.12 Recording. Either Party will have the right, at any time, to record,
register, or otherwise notify this Agreement in appropriate governmental or
regulatory offices anywhere within the Territory, and the other Party will
provide reasonable assistance to the recording, registering or notifying Party
in effecting such recording, registering or notifying and provided that the
other Party will have the opportunity to consult in advance on such disclosures
and filings.

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.


                                       17
<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have duly executed this Generic
Distribution Agreement as of the date first above written.

                                        KING PHARMACEUTICALS, INC.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------


                                        COBALT PHARMACEUTICALS, INC.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

                        CONFIDENTIAL TREATMENT REQUESTED


 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.
<PAGE>

                                   APPENDIX 1

                                 PURCHASE ORDER

     All purchase orders from Cobalt for Generic Product will include the
following information:

[***]










    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
      THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION
      REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES
                              EXCHANGE ACT OF 1934.